Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment

NCT01022762 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

440

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: repaglinide
DRUG: gliclazide

Sponsor

Novo Nordisk A/S